Proteostasis Files for a $86 Million IPO

Proteostasis Therapeutics, which is developing combination therapeutics that use amplifier molecules to modulate proteins, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering.

The Cambridge, MA-based company, which was founded in 2006 and booked $4 million in sales for the 12 months ended September 30, 2015, plans to list on the Nasdaq under the symbol PTI.

Back to news